DRKS00011663已完成4 期
Modelling the impact of PCSK9 inhibitors on lipoproteins in patients with dyslipidemia
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Written consent
- •conditions for a therapy with PCSK9-inhibitors are given
排除标准
- •1.severe Liver-disease g (Child-Pugh C) 2. severe renal insufficiency 3.TSH not im reference range 4. uncontrolled aterial hypertension: Diastolic RR >=105 mmHg and/or systolic RR >=160 mmHg. 5.alcohol abuse or other drug abuse (except smoking) 6. blood donation within the last 6 weeks before the screening 7. Patients with a severe acute disease 8.HbA1c > 8.0% 9. Other important severe internistic diseases, which may alter the lipidmetabolism 10.hypersensitivity against the substance 11.pregnancy oder planned pregnancy and lactation period
研究者
相似试验
进行中（未招募）
1 期
Mathematical modeling of the impact of 'PCSK9 inhibitior'-drugs on the fat metabolism in patients with an impaired fat metabolismdyslipidemiaEUCTR2016-003551-30-DEniversitätsklinikum Freiburg30
已完成
不适用
egacy Effects of PCSK9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaqueacute coronary syndromeJPRN-UMIN000041925Gifu Heart Center7
招募中
不适用
Impact of PCSK9 Inhibitor on the Characteristics of Lipid-rich Coronary Plaques Assessed by Near-infrared SpectroscopyIschemic Heart DiseaseJPRN-UMIN000040318Gifu Heart Center50
Unknown
2 期
PCSK9 Inhibitors in the Progression of Aortic StenosisAortic Valve StenosisNCT03051360Seoul National University Hospital140
已完成
不适用
Efficacy and safety of PCSK9 inhibitor for dyslipidemiarefractory dyslipidemiaJPRN-UMIN000023483Sekino Hospital70